Similar articles

• Androgen deprivation therapy for prostate cancer and cardiovascular death.

  Blankfield RP. Blankfield RP. JAMA. 2012 Mar 28;307(12):1252; author reply 1252-3. doi: 10.1001/jama.2012.352. JAMA. 2012. PMID: 22453560 No abstract available.
• Prostate cancer: cardiovascular mortality and androgen deprivation.

  Basaria S. Basaria S. Nat Rev Urol. 2009 May;6(5):252-3. doi: 10.1038/nrurol.2009.75. Nat Rev Urol. 2009. PMID: 19424172
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK. Nguyen PL, et al. JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745. JAMA. 2011. PMID: 22147380
• Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.

  Tivesten Å, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Tivesten Å, et al. Urol Oncol. 2015 Nov;33(11):464-75. doi: 10.1016/j.urolonc.2015.05.030. Epub 2015 Jun 30. Urol Oncol. 2015. PMID: 26141678 Review.
• Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

  Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F. Sciarra A, et al. Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Eur Urol. 2013. PMID: 23628492 Review.